Core Insights - NewAmsterdam Pharma is set to present additional pooled safety and efficacy data from the pivotal Phase 3 BROADWAY and BROOKLYN trials at the European Society of Cardiology Congress (ESC) from August 29 to September 1, 2025 [1] - The company is focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol [1][5] Presentation Details - The first presentation titled "Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomized trials" will take place on August 29, 2025, at 10:10 am CEST [2] - A second presentation titled "Obicetrapib and cardiovascular events" is scheduled for September 1, 2025, at 9:00 am CEST [3] Upcoming Investor Conferences - NewAmsterdam management will participate in several investor conferences, including: - Citi's 2025 Biopharma Back to School Summit on September 3, 2025, at 2:30 pm ET in Boston, MA [4] - Cantor Global Healthcare Conference on September 4, 2025, at 2:45 pm ET in New York, NY [4] - Wells Fargo Healthcare Conference on September 5, 2025, at 10:15 am ET in Boston, MA [4] - Live webcasts of these presentations will be available on the company's investor relations website [4]

Company Overview - NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C) [1][3] - The company aims to address the unmet need for safe, well-tolerated, and convenient LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [3] Product Development - NewAmsterdam is conducting multiple phase 3 trials for obicetrapib, an oral, low-dose, once-daily CETP inhibitor, which is being investigated as a standalone treatment and in combination with ezetimibe [3] - The target population includes patients at risk of CVD with elevated LDL-C levels, for whom current therapies are insufficiently effective or poorly tolerated [3] Upcoming Events - Ian Somaiya, the Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2025 RBCCM Global Healthcare Conference on May 20, 2025, at 10:00 a.m. ET [1] - A live webcast of the event will be available on the investor relations section of the NewAmsterdam Pharma website, with an archived replay to follow [2]

Core Insights - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol [1][3] - The company aims to address the unmet need for safe and well-tolerated LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [3] Company Overview - NewAmsterdam Pharma is investigating obicetrapib, a low-dose, once-daily CETP inhibitor, in multiple phase 3 trials [3] - The therapy is being studied both as a standalone treatment and in combination with ezetimibe, intended to complement statin therapy for patients with elevated LDL-C [3] Upcoming Events - Ian Somaiya, the Chief Financial Officer, will participate in a virtual fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025 [1] - A live webcast of the event will be available on the company's investor relations website, with an archived replay to follow [2]